These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9572049)

  • 1. Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children.
    Alonso PL; Lopez MC; Bordmann G; Smith TA; Aponte JJ; Weiss NA; Urassa H; Armstrong-Schellenberg JR; Kitua AY; Masanja H; Thomas MC; Oettli A; Hurt N; Hayes R; Kilama WL; Tanner M
    Parasite Immunol; 1998 Feb; 20(2):63-71. PubMed ID: 9572049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune responses during a malaria vaccine trial in Tanzanian infants.
    Galindo CM; Acosta CJ; Schellenberg D; Aponte JJ; Roca A; Oettli A; Urassa H; Armstrong Schellenberg J; Kahigwa E; Ascaso C; Mshinda H; Lwilla F; Vidal J; Menendez C; Tanner M; Alonso PL
    Parasite Immunol; 2000 Sep; 22(9):437-43. PubMed ID: 10972850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationships with clinical malaria and with entomological inoculation rates.
    Kitua AY; Urassa H; Wechsler M; Smith T; Vounatsou P; Weiss NA; Alonso PL; Tanner M
    Parasite Immunol; 1999 Jun; 21(6):307-17. PubMed ID: 10354353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological responses of Gambian children to immunization with the malaria vaccine SPf66.
    Metzger WG; Haywood M; D'Alessandro U; Drakeley CJ; Weiss H; Bojang K; Targett GA; Greenwood BM
    Parasite Immunol; 1999 Jul; 21(7):335-40. PubMed ID: 10417667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy trial of malaria vaccine SPf66 in Gambian infants.
    D'Alessandro U; Leach A; Drakeley CJ; Bennett S; Olaleye BO; Fegan GW; Jawara M; Langerock P; George MO; Targett GA
    Lancet; 1995 Aug; 346(8973):462-7. PubMed ID: 7637479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2003; (1):CD000129. PubMed ID: 12535387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WITHDRAWN: Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2007 Jul; 2003(4):CD000129. PubMed ID: 17636596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66.
    Millet P; Campbell GH; Sulzer AJ; Grady KK; Pohl J; Aikawa M; Collins WE
    Am J Trop Med Hyg; 1993 Mar; 48(3):424-31. PubMed ID: 7682382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66.
    Beck HP; Felger I; Huber W; Steiger S; Smith T; Weiss N; Alonso P; Tanner M
    J Infect Dis; 1997 Apr; 175(4):921-6. PubMed ID: 9086150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response to the anti-malaria vaccine SPf66 in the Colombian Atrato River region.
    Lopera TM; Restrepo M; Blair S; García HI
    Mem Inst Oswaldo Cruz; 1998; 93(4):495-500. PubMed ID: 9711340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in the mean number of Plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66.
    Haywood M; Conway DJ; Weiss H; Metzger W; D'Alessandro U; Snounou G; Targett G; Greenwood B
    Trans R Soc Trop Med Hyg; 1999 Feb; 93 Suppl 1():65-8. PubMed ID: 10450429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
    Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
    Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria.
    al-Yaman F; Genton B; Anders R; Taraika J; Ginny M; Mellor S; Alpers MP
    Parasite Immunol; 1995 Sep; 17(9):493-501. PubMed ID: 8552419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
    Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
    Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.
    Alonso PL; Smith T; Schellenberg JR; Masanja H; Mwankusye S; Urassa H; Bastos de Azevedo I; Chongela J; Kobero S; Menendez C
    Lancet; 1994 Oct; 344(8931):1175-81. PubMed ID: 7934537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic Antigens Derived from
    Pratt-Riccio LR; De Souza Perce-Da-Silva D; Da Costa Lima-Junior J; Pratt Riccio EK; Ribeiro-Alves M; Santos F; Arruda M; Camus D; Druilhe P; Oliveira-Ferreira J; Daniel-Ribeiro CT; Banic DM
    Am J Trop Med Hyg; 2017 Nov; 97(5):1581-1592. PubMed ID: 29016339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission.
    Teuscher T; Schellenberg JR; Bastos de Azevedo I; Hurt N; Smith T; Hayes R; Masanja H; Silva Y; Lopez MC; Kitua A
    Vaccine; 1994 Mar; 12(4):328-36. PubMed ID: 8178555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the humoral and cell-mediated immunity against the Plasmodium falciparum vaccine candidates circumsporozoite protein and SPf66 in adults living in highly endemic malarious areas of Papua New Guinea.
    Beck HP; Felger I; Kabintik S; Tavul L; Genton B; Alexander N; Bhatia KK; al-Yaman F; Hii J; Alpers M
    Am J Trop Med Hyg; 1994 Sep; 51(3):356-64. PubMed ID: 7943557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants.
    Leach A; Drakeley CJ; D'Alessandro U; Fegan GW; Bennett S; Ballou WR; Targett GA; Greenwood BM
    Parasite Immunol; 1995 Aug; 17(8):441-4. PubMed ID: 7501425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.
    Jäschke A; Coulibaly B; Remarque EJ; Bujard H; Epp C
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.